Dr. Andreas Meinke graduated in Biology from the University of Freiburg, Germany and obtained his Ph.D. in 1992 from the University of Freiburg and the University of British Columbia in Vancouver, Canada. Subsequent to his work at the Department of Microbiology and Immunology at UBC, he joined the Department of Microbiology and Genetics, University Vienna, as an Assistant Professor.
In 1998, Dr. Meinke joined the newly founded biotech company Intercell AG (now Valneva SE), where he was instrumental for the development of the AIP technology that led to the development of several vaccines, currently in pre-clinical and clinical development. At Valneva, he held various positions and was appointed in 2014 to head the Pre-clinical & Translational Research at Valneva, responsible for all pre-clinical and translational research activities in Vienna.
During his career, Dr. Meinke has authored and co-authored more than 70 publications lectured in several University programs and filed more than 20 patents in the field of antigen discovery.